KRAS and familial pancreatic carcinoma: Following these results the authors validated their finding through mining CRISPR–cas9 dependency data, drug screens and western blot endpoints showed that targeting CDK hyperactivation may be an effective way of treating KRAS mutant pancreatic cancer.